LONDONGlaxoSmithKline PLC announced new cost savings plans to explore a partial listing of its ViiV Healthcare business and betterthanexpected earnings Wednesday as the beleaguered drug maker responds to pressures in the US that continue to drag down its sales  Glaxos sales fell  to  billion  billion in the third quarter disappointing analysts as revenue from Advair the companys single bestselling drug continued its sharp decline 